Q-omics provides the consensus-scored GAL profile across patient tissues and cancer cell-line models. GAL expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, GAL is differentially expressed in 13, with the highest sampling consensus in LUAD. Additionally, GAL RNA expression shows 14,479 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight LUAD, and BRCA as cancer lineages where GAL shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GAL — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GAL survival associations across molecular data types. GAL RNA expression shows survival associations in the most cancer types (29), followed by mutation status (3) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GAL RNA expression–survival associations across cancer types. High GAL expression shows unfavorable associations in LUAD, UCEC, ACC, SKCM, UCS and COAD. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for GAL RNA expression.
This table summarizes GAL tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 3. The strongest signals are observed in LUAD for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for GAL. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GAL shows lower tumor expression in KIRC and higher tumor expression in LUAD, LUSC, HNSC, UCEC and BLCA. The LUAD box plot shows higher GAL RNA expression in tumor versus normal tissue (log2 FC = +2.113, t-test p < 0.001).
This table shows molecular features associated with GAL in patient tissues and cancer cell lines. In patient samples, GAL shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, GAL RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
